Thursday December 7, 2017 0 comments
LAKEWOOD -- The Department of Defense recently awarded Terumo BCT a three-year grant to explore the feasibility of further advancing blood safety by reducing pathogens in blood transfused to military personnel using the Mirasol® Pathogen Reduction Technology System.
Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular technologies.
The amount of the DOD grant was not disclosed.
Mirasol uses riboflavin, also known as vitamin B2, and ultraviolet light to reduce the pathogen load of various disease-causing viruses, bacteria and parasites in blood products before they are transfused to patients.
The technology is already used in more than 20 countries throughout Europe, the Middle East, Africa, Asia and Latin America.
Terumo BCT will use the technology/therapeutic development award from the Peer Reviewed Medical Research Program, which is part of the DOD's Congressionally Directed Medical Research Programs.
The goal is to develop the next-generation of Mirasol, which could be the first blood component technology capable of reducing pathogens in whole blood before separating it into components, the company said.
"A ready and safe supply of blood products for our warfighters and beneficiaries around the world is fundamental to preparedness,” said Col. Audra L. Taylor, director of the Army Blood Program.
“This new grant extends our efforts with Terumo BCT to help us further explore increasing blood processing and pathogen reduction efficiencies.”
Compared to today's Mirasol, Terumo said the next generation will have the potential to enable a faster turnaround from blood donation to transfusion.
"Our latest DOD grant is helping Terumo BCT directly address specific customer needs by engineering innovations that will have a lasting impact on patients throughout the world," said Palani Palaniappan, Terumo executive VP for innovation and development.